The European Medicines Agencys 2025 synthetic peptide quality guideline treats peptide-related impurities as first-class critical quality attributes: deletion and truncated sequences, dimers, oligomers, and degradation products each need characterization, with European Pharmacopoeia practice pointing to reporting thresholds at 0.1% and identification thresholds above 0.5% for peptide-related impurities in pharmaceutical use
FDA compounding review On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 (free base) and AOD-9604 acetate against the 503A Bulks List
It closely resembles the human GLP-1 hormone in structure (about 94% similarity), allowing it to mimic its effects on blood sugar control and digestion
Jumping to higher doses too quickly dramatically increases the risk of severe nausea, vomiting, and other GI side effects
Should I stop taking semaglutide